# The Sagittarius Trial

Source: https://onco.cc/trials/nct06490536/  
OnCo record `nct06490536` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine, leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in colorectal cancer, run by IFOM ETS - The AIRC Institute of Molecular Oncology, now recruiting.

## Summary

The Sagittarius Trial is a phase 3, randomised interventional study registered as NCT06490536 by IFOM ETS - The AIRC Institute of Molecular Oncology, with a registry enrolment figure of 700 participants, started 2024-10-22 and due to reach its primary completion in 2026-03-01. Interventions recorded: Oxaliplatin; Capecitabine; Folinic acid; Fluorouracil; Temozolomide; Irinotecan; Nivolumab; Ipilimumab; Trastuzumab; Pertuzumab; Panitumumab. Conditions listed: Colon Cancer Stage II; Colon Cancer Stage III. Primary outcome: 2-Year Recurrence-Free Survival (RFS). Sites: Germany, Italy, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06490536
- Phase: 3
- Setting: A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients
- Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT06490536: https://clinicaltrials.gov/study/NCT06490536

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Temozolomide](https://onco.cc/drugs/temozolomide/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06490536.json